ENGINEERING NME2CAS9 AND SPYCAS9 FOR IMPROVED GENE EDITING ACTIVITIES

Tech ID: 33367 / UC Case 2024-059-0

PATENT STATUS

Patent Pending

BRIEF DESCRIPTION

UC Berkeley researchers have created variant CRISPR-Cas effector polypeptides (e.g., variant Cas9 proteins) with improved properties, such as improved editing efficiency and/or improved PAM sequence flexibility, as well as methods of modifying a target nucleic acid using a variant CRISPR-Cas effector polypeptide and methods of generating variant CRISPR-Cas effector polypeptides.

SUGGESTED USES

- In vivo gene editing
- Therapeutic applications

CONTACT

Terri Sale
terri.sale@berkeley.edu
tel: 510-643-4219.

OTHER INFORMATION

KEYWORDS

Nme2Cas9 variants, SpyCas9 variants

CATEGORIZED AS

- **Biotechnology**
  - Genomics
- **Medical**
  - Gene Therapy
  - Research Tools
- **Research Tools**
  - Nucleic Acids/DNA/RNA

RELATED CASES

2024-059-0